TGF-β and IL-17 serum levels and specific immunotherapy

Giorgio Ciprandi, Mara De Amici, Simone Negrini, Gianluigi Marseglia, Maria Angela Tosca

Research output: Contribution to journalArticlepeer-review


Two new T cell subsets may be involved in allergic rhinitis (AR) pathogenesis: Th17 and T regulatory cells, mainly producing IL-17 and TGF-β respectively. Successful Sublingual Immunotherapy (SLIT) induces relevant immunological changes, thus the aim of this study was to evaluate serum IL-17 and TGF-β levels in AR patients treated with SLIT for 2 years. Patients' blood samples were collected before initiating SLIT (baseline), three months after the end of the first pre-seasonal SLIT course, and at the end of the second pre-seasonal course. IL-17 was detectable only in the most severe allergic patients. SLIT significantly induced an increase in serum TGF-β levels. There was moreover a significant relationship between TGF-β and symptom severity and drug use at the end of the study. Therefore, this study provides clinically relevant evidence that two pre-seasonal SLIT courses may significantly affect serum TGF-β levels.

Original languageEnglish
Pages (from-to)1247-1249
Number of pages3
JournalInternational Immunopharmacology
Issue number10
Publication statusPublished - Sep 2009


  • Allergic rhinitis
  • IL-17
  • Sublingual immunotherapy
  • TGF-β

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pharmacology


Dive into the research topics of 'TGF-β and IL-17 serum levels and specific immunotherapy'. Together they form a unique fingerprint.

Cite this